Switching to certain antidiabetic drugs linked to increased risk of major complications

July 18, 2018, British Medical Journal
Credit: CC0 Public Domain

For people with type 2 diabetes, switching to sulfonylurea drugs to control blood sugar levels is associated with an increased risk of complications compared with staying on the drug metformin, finds a study in The BMJ today.

As such, the researchers say that continuing metformin when introducing sulfonylureas is safer than switching.

Metformin is a "first-line" therapy (the first drug that will be tried) for patients with type 2 diabetes. But sulfonylureas are the most commonly prescribed "second line" treatment, and often used in combination with metformin.

The safety of sulfonylureas has been studied extensively. However, little is known about the specific risk of adding or switching to sulfonylureas compared with staying on metformin treatment alone.

So a research team, led by Professor Samy Suissa at McGill University in Canada, set out to assess whether adding or switching to sulfonylureas is associated with an increased risk of serious complications, compared with remaining on metformin alone in patients with type 2 diabetes.

They analysed data from the UK Clinical Practice Research Datalink for over 77,000 patients (average age 64 years) with type 2 diabetes who started metformin treatment between 1998 and 2013.

Patients who subsequently added or switched to a sulfonylurea were identified and matched to a similar patient who continued metformin alone.

Hospital records were then used to monitor admissions for (myocardial infarction) and ischaemic stroke, , death from any cause ("all cause mortality"), and dangerously low (severe hypoglycemia).

During an average follow-up period of just over a year, sulfonylurea use (switching and adding combined) was associated with an increased risk of heart attack (7.8 v 6.2 per 1000 person years), all cause mortality (27.3 v 21.5), and severe hypoglycaemia (5.5 v 0.7), compared with continuing metformin alone.

There was also a trend towards increased risks of ischaemic stroke (6.7 v 5.5 per 1000 person years) and cardiovascular death (9.4 v 8.1) with sulfonylurea use.

Compared with adding sulfonylureas to metformin treatment, switching to sulfonylureas was associated with a greater risk of heart attack and all cause mortality, but no differences were found for ischaemic stroke, cardiovascular death, or severe hypoglycaemia.

Findings remained similar after further analyses to test the strength of the results.

This is an observational study, so cannot establish cause and effect, and the researchers say they cannot rule out the possibility that some of the observed risk may be due to other unmeasured (confounding) factors. Nevertheless, they say their results are highly generalisable and the large sample size allowed the calculation of precise estimates.

As such, they conclude that sulfonylureas as second line drugs "are associated with an increased risk of myocardial infarction, all cause mortality, and severe hypoglycaemia, compared with remaining on metformin monotherapy."

Importantly, the associations with and all cause mortality "were driven by switching to sulfonylureas and not the addition of sulfonylureas," they add. "Thus, in line with current recommendations on the treatment of type 2 diabetes, continuing when introducing sulfonylureas is safer than switching."

In a linked editorial, US researchers Lucy D'Agostino McGowan and Christianne Roumie, say this new evidence helps to individualise decisions and minimise harm.

They point out that it is hard to define based on an observational study, as using different therapies may differ in ways that are unmeasured. However, they say this study "is well designed and the relationships appear strong and consistent."

Explore further: CVD risk similar for metformin + insulin or sulfonylureas

More information: Sulfonylureas as second line drugs in type 2 diabetes and the risk of cardiovascular and hypoglycaemic events: population based cohort study, The BMJ, www.bmj.com/content/362/bmj.k2693

Editorial: Sulfonylureas as second line treatment for type 2 diabetes, The BMJ, www.bmj.com/content/362/bmj.k3041

Related Stories

CVD risk similar for metformin + insulin or sulfonylureas

July 20, 2015
(HealthDay)—For patients with type 2 diabetes, the risk of myocardial infarction (MI) or stroke is similar for treatment with insulin or sulfonylureas in combination with metformin, according to a study published online ...

First-line metformin use for DM up; sulfonylurea use down

November 19, 2017
(HealthDay)—Among patients with type 2 diabetes initiating antidiabetes drugs (ADDs), first-line use of metformin has increased since 2005, while sulfonylureas have remained the most popular second-line agent, according ...

Sulfonylureas up cardio events versus metformin

November 7, 2012
(HealthDay)—Use of sulfonylureas for initial treatment of diabetes is associated with increased cardiovascular events and death compared with metformin, according to a study published in the Nov. 6 issue of the Annals of ...

Metformin linked to increased risk of acute dialysis in T2DM

August 23, 2016
(HealthDay)—For patients with type 2 diabetes, metformin is associated with about a 50 percent increase in the risk of acute dialysis compared to sulfonylureas, according to a study published online Aug. 18 in Diabetes, ...

Metformin use doesn't cut incidence of bladder cancer

February 11, 2014
(HealthDay)—For patients with type 2 diabetes, metformin use is not associated with a significantly reduced risk of bladder cancer, according to a study published online Feb. 4 in Diabetes Care.

Common diabetes drugs may carry risk, study suggests

September 26, 2013
(HealthDay)—Diabetes patients who take drugs called sulfonylureas as an initial therapy have a higher risk of death than those who take the diabetes drug metformin, a new study says.

Recommended for you

Does diabetes damage brain health?

December 14, 2018
(HealthDay)—Diabetes has been tied to a number of complications such as kidney disease, but new research has found that older people with type 2 diabetes can also have more difficulties with thinking and memory.

Researchers study abnormal blood glucose levels of discharged patients

December 14, 2018
University of Minnesota Medical School researchers decided to delve into an area where little data currently exists. They wanted to know what happens after these patients with abnormal blood glucose measurements are discharged? ...

Researchers zero in on potential therapeutic target for diabetes, associated diseases

December 14, 2018
A recent study led by researchers in Texas A&M University's department of nutrition and food science shows how a novel regulatory mechanism serves as an important biomarker for the development of diabetes, as well as a potential ...

Researchers have found that incidence of heart failure was around two-fold higher in people with diabetes

December 11, 2018
Researchers have found that incidence of heart failure was around two-fold higher in people with diabetes.

Millions of low-risk people with diabetes may be testing their blood sugar too often

December 10, 2018
For people with Type 2 diabetes, the task of testing their blood sugar with a fingertip prick and a drop of blood on a special strip of paper becomes part of everyday life.

Very low calorie diets trialled by NHS to tackle diabetes

December 7, 2018
Hundreds of thousands of people will receive NHS help to battle obesity and type 2 diabetes under radical action set out by Simon Stevens, Chief Executive of NHS England.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.